New drug trial seeks to calm overactive immune system
NCT ID NCT06799520
Summary
This is a first-in-human study to check if a new injectable drug called VIS171 is safe for people with certain autoimmune diseases like lupus, alopecia areata, or a kidney disease called FSGS. About 30 participants will receive the drug along with their standard care for up to a year. The main goal is to see how well the drug is tolerated and to measure its effects on specific immune cells in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Visterra Investigational Site
RECRUITINGSofia, 1404, Bulgaria
-
Visterra Investigational Site
RECRUITINGChisinau, MD-2025, Moldova
-
Visterra Investigational Site
RECRUITINGBucharest, 11658, Romania
-
Visterra Investigational Site
RECRUITINGCluj-Napoca, 40006, Romania
-
Visterra Investigational Site
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Visterra Investigational Site
NOT_YET_RECRUITINGGranada, 18014, Spain
Conditions
Explore the condition pages connected to this study.